|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.670 USD | +11.33% |
|
-.--% | +221.15% |
| 06-01 | Revium Rx. Announces CFO Changes, Effective May 27, 2026 | CI |
| 05-14 | Revium Rx. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
Profitability | ||||
Return on Assets | - | -13.96 | -20.42 | -15.15 |
Return on Total Capital | - | -14.46 | -21.14 | -16.22 |
Return On Equity % | - | -23.25 | -33.23 | -101.17 |
Return on Common Equity | - | -23.25 | -20.5 | -104.19 |
Short Term Liquidity | ||||
Current Ratio | 6.53 | 39.08 | 9.58 | 2.26 |
Quick Ratio | 6.24 | 38.13 | 9.24 | 2.03 |
Operating Cash Flow to Current Liabilities | -11.73 | -4.37 | -2.1 | -1.85 |
Long Term Solvency | ||||
Total Debt/Equity | 0.26 | 0.02 | 0 | 1.48 |
Total Debt / Total Capital | 0.26 | 0.02 | 0 | 1.46 |
LT Debt/Equity | - | - | - | 0.67 |
Long-Term Debt / Total Capital | - | - | - | 0.66 |
Total Liabilities / Total Assets | 15.22 | 2.56 | 2.84 | 17.06 |
EBIT / Interest Expense | -54.14 | -226.67 | -1.78K | - |
EBITDA / Interest Expense | -54.05 | -226 | -1.78K | - |
(EBITDA - Capex) / Interest Expense | -54.14 | -226.33 | -1.78K | - |
Total Debt / EBITDA | -0 | -0 | -0 | -0.03 |
Net Debt / EBITDA | 0.36 | 8.08 | 1.48 | 0.75 |
Total Debt / (EBITDA - Capex) | -0 | -0 | -0 | -0.03 |
Net Debt / (EBITDA - Capex) | 0.36 | 8.07 | 1.48 | 0.75 |
Growth Over Prior Year | ||||
EBITDA, 1 Yr. Growth % | - | -42.98 | 256.04 | -2.97 |
EBITA, 1 Yr. Growth % | - | -42.91 | 256.09 | -2.91 |
EBIT, 1 Yr. Growth % | - | -42.91 | 256.09 | -2.91 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | -43.69 | 255.12 | 283.71 |
Net Income, 1 Yr. Growth % | - | -43.69 | 255.12 | 283.71 |
Normalized Net Income, 1 Yr. Growth % | - | -43.69 | 255.12 | -2.8 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | -46.09 | - | 61.96 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | -33.33 | 350 | 1.33K |
Total Assets, 1 Yr. Growth % | - | 1.12K | 1.2K | -59.1 |
Tangible Book Value, 1 Yr. Growth % | - | 1.31K | 200.29 | -56.72 |
Common Equity, 1 Yr. Growth % | - | 1.31K | 1.26K | -63.66 |
Cash From Operations, 1 Yr. Growth % | - | -23.39 | 19.43 | 109 |
Capital Expenditures, 1 Yr. Growth % | - | -50 | 0 | 133.33 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | -145.99 | -413.79 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | -146.18 | -412.5 |
Compound Annual Growth Rate Over Two Years | ||||
EBITDA, 2 Yr. CAGR % | - | - | 73.13 | 85.86 |
EBITA, 2 Yr. CAGR % | - | - | 73.08 | 85.93 |
EBIT, 2 Yr. CAGR % | - | - | 73.08 | 85.93 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 69.99 | 269.14 |
Net Income, 2 Yr. CAGR % | - | - | 69.99 | 269.14 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 69.99 | 85.79 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -10.82 | - |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 73.21 | 703.12 |
Total Assets, 2 Yr. CAGR % | - | - | 564.01 | 130.68 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 227.38 | 14 |
Common Equity, 2 Yr. CAGR % | - | - | 596.81 | 122.33 |
Cash From Operations, 2 Yr. CAGR % | - | - | 21.45 | 57.99 |
Capital Expenditures, 2 Yr. CAGR % | - | - | 22.47 | 52.75 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 20.13 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 20.13 |
Compound Annual Growth Rate Over Three Years | ||||
EBITDA, 3 Yr. CAGR % | - | - | - | 42.74 |
EBITA, 3 Yr. CAGR % | - | - | - | 42.74 |
EBIT, 3 Yr. CAGR % | - | - | - | 42.74 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 122.99 |
Net Income, 3 Yr. CAGR % | - | - | - | 122.99 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 41.09 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | 72.49 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 250.34 |
Total Assets, 3 Yr. CAGR % | - | - | - | 162.24 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 66.77 |
Common Equity, 3 Yr. CAGR % | - | - | - | 160.33 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 45.54 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 51.83 |
- Stock Market
- Stocks
- RVRC Stock
- Financials Revium Rx.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















